Brief Report: Preexposure Prophylaxis Use Among U.S. Veterans Using Veterans Health Administration Services, 2014─2022

J Acquir Immune Defic Syndr. 2025 Jan 1;98(1):8-11. doi: 10.1097/QAI.0000000000003532.

Abstract

Objectives: It is important to monitor national HIV preexposure prophylaxis (PrEP) use in the United States. However, PrEP use data in the Veterans Health Administration (VHA) system are not included in the current monitoring surveillance. To address this gap, we examined the trends in PrEP use among U.S. Veterans receiving health services in the VHA system.

Methods: We analyzed 2014-2022 VHA data to identify the annual number and prevalence of persons aged ≥18 years prescribed PrEP, stratified by sex, age, race/ethnicity, and region. We also assessed trends by calculating the estimated annual percent change and 95% confidence intervals using Poisson models.

Results: The number of Veterans prescribed PrEP increased from 361 in 2014 to 6050 in 2022 with an estimated annual percent change of 29.6% (95% CI: 22.6 to 37.1). Of 6050 Veterans with PrEP prescriptions in 2022, 95.2% were men, 4.8% were women, 50.4% were White, 24.5% Black or African American (Black), and 14.0% Hispanic or Latino. The prevalence of Black and Hispanic or Latino individuals prescribed PrEP increased significantly from 2014 to 2022.

Conclusions: VHA data fill a gap in monitoring PrEP use in the United States. We observed an increasing trend in the number of Veterans prescribed PrEP similar to trends among persons with commercial or public health insurance.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Anti-HIV Agents / administration & dosage
  • Anti-HIV Agents / therapeutic use
  • Female
  • HIV Infections* / epidemiology
  • HIV Infections* / prevention & control
  • Humans
  • Male
  • Middle Aged
  • Pre-Exposure Prophylaxis* / statistics & numerical data
  • United States
  • United States Department of Veterans Affairs
  • Veterans Health Services* / statistics & numerical data
  • Veterans* / statistics & numerical data
  • Young Adult

Substances

  • Anti-HIV Agents